On the public citation graph
Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis
0 signed · 67 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/art.11015openalex-snapshot
The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: A five‐year followup study
inferredcites →https://doi.org/10.1002/art.1780310302openalex-snapshot
The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis
inferredcites →https://doi.org/10.1002/art.1780401016openalex-snapshot
Clinical, laboratory, radiographic, and histopathologic features of methotrexate‐associated lung injury in patients with rheumatoid arthritis. A multicenter study with literature review
inferredcites →https://doi.org/10.1002/art.20861openalex-snapshot
Long‐term open‐label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular‐course juvenile rheumatoid arthritis
inferredcites →https://doi.org/10.1002/art.21806openalex-snapshot
Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis
inferredcites →https://doi.org/10.1016/s0140-6736(04)15527-xopenalex-snapshot
Japan deaths spark concerns over arthritis drug
inferredcites →https://doi.org/10.1016/s0149-2918(04)90048-3openalex-snapshot
Leflunomide in the treatment of rheumatoid arthritis
inferredcites →https://doi.org/10.1097/00006416-199003000-00011openalex-snapshot
Revised Criteria for the Classification of Rheumatoid Arthritis
inferredcites →https://doi.org/10.1136/ard.60.10.913openalex-snapshot
Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine
inferredcites →https://doi.org/10.2169/internalmedicine.43.1201openalex-snapshot
Rheumatoid Arthritis Complicated with Acute Interstitial Pneumonia Induced by Leflunomide as an Adverse Reaction
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4866588openalex-extracted
The Pathogenesis of Rheumatoid Arthritis Associated Interstitial Lung Disease and the Progress in the Treatment of Traditional Chinese Medicine
inferred← citeshttps://doi.org/10.1002/14651858.cd002047openalex-snapshot
Leflunomide for the treatment of rheumatoid arthritis
inferred← citeshttps://doi.org/10.1007/978-3-319-68888-6_9openalex-snapshot
Management of the Rheumatoid Arthritis Patient with Interstitial Lung Disease
inferred← citeshttps://doi.org/10.1007/s00296-009-1222-yopenalex-snapshot
Development of antisynthetase syndrome in a patient with rheumatoid arthritis
inferred← citeshttps://doi.org/10.1007/s00296-009-1240-9openalex-snapshot
Recurrent pneumothorax associated with pulmonary nodules after leflunomide therapy in rheumatoid arthritis: a case report and review of the literature
inferred← citeshttps://doi.org/10.1007/s00296-020-04744-9openalex-snapshot
COVID-19 pandemic in Japan
inferred← citeshttps://doi.org/10.1007/s10067-020-05227-9openalex-snapshot
Non-anti-TNF biologic agents are associated with slower worsening of interstitial lung disease secondary to rheumatoid arthritis
inferred← citeshttps://doi.org/10.1007/s40674-025-00239-5openalex-snapshot
Treatment Algorithms for Inflammatory Myopathies in Adults: from Guidelines to Clinical Practice
inferred← citeshttps://doi.org/10.1007/s40744-017-0071-5openalex-snapshot
Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis
inferred← citeshttps://doi.org/10.1016/b978-0-323-44887-1.00059-6openalex-snapshot
Lung Injury Caused by Pharmacologic Agents
inferred← citeshttps://doi.org/10.1016/b978-0-444-53717-1.00963-xopenalex-snapshot
Leflunomide and teriflunomide
inferred← citeshttps://doi.org/10.1016/b978-1-4160-4710-0.00058-4openalex-snapshot
The Lungs and Connective Tissue Diseases
inferred← citeshttps://doi.org/10.1016/b978-1-4377-1984-0.00074-7openalex-snapshot
Lung Injury Caused by Pharmacologic Agents
inferred← citeshttps://doi.org/10.1016/b978-1-4557-3383-5.00065-8openalex-snapshot
Connective Tissue Diseases
inferred← citeshttps://doi.org/10.1016/j.berh.2011.10.009openalex-snapshot
Co-morbidities in established rheumatoid arthritis
inferred← citeshttps://doi.org/10.1016/j.berh.2016.10.004openalex-snapshot
Lung involvement in inflammatory rheumatic diseases
inferred← citeshttps://doi.org/10.1016/j.hrtlng.2013.11.007openalex-snapshot
Pulmonary toxicity associated with the use of lenalidomide: Case report of late-onset acute respiratory distress syndrome and literature review
inferred← citeshttps://doi.org/10.1016/j.lpm.2010.11.003openalex-snapshot
The lung in rheumatoid arthritis
inferred← citeshttps://doi.org/10.1016/j.lungcan.2009.10.007openalex-snapshot
Interstitial pneumonia probably associated with sorafenib treatment: An alert of an adverse event
inferred← citeshttps://doi.org/10.1016/j.reuma.2022.03.005openalex-snapshot
Recomendaciones SER-SEPAR para el manejo de la enfermedad pulmonar intersticial difusa asociada a la artritis reumatoide. Parte 2: tratamiento
inferred← citeshttps://doi.org/10.1016/j.reumae.2022.03.004openalex-snapshot
SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 2: Treatment
inferred← citeshttps://doi.org/10.1016/j.rmcr.2021.101468openalex-snapshot
Leflunomide-induced interstitial pneumonitis: A rare occurrence in a case without underlying lung disease
inferred← citeshttps://doi.org/10.1016/j.semarthrit.2013.09.005openalex-snapshot
Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: A systematic literature review
inferred← citeshttps://doi.org/10.1016/s0378-6080(06)29038-xopenalex-snapshot
38 Drugs that act on the immune system: immunosuppressive and immunostimulatory drugs
inferred← citeshttps://doi.org/10.1016/s0378-6080(10)32038-1openalex-snapshot
Drugs that act on the immune system: immunosuppressive and immunostimulatory drugs
inferred← citeshttps://doi.org/10.1080/1744666x.2024.2407536openalex-snapshot
Interstitial lung disease in rheumatic diseases: an update of the 2018 review
inferred← citeshttps://doi.org/10.1093/ndt/gfq746openalex-snapshot
Interstitial lung diseases after leflunomide use in nephropathy: an analysis of reported cases in Chinese literature
inferred← citeshttps://doi.org/10.1093/rheumatology/keac651openalex-snapshot
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease
inferred← citeshttps://doi.org/10.1093/rheumatology/kep050openalex-snapshot
Clinical expression of leflunomide-induced pneumonitis
inferred← citeshttps://doi.org/10.1093/rheumatology/kep052openalex-snapshot
Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis
inferred← citeshttps://doi.org/10.1097/01.fad.0000286805.02496.4dopenalex-snapshot
Adverse reactions and safety of newer disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis
inferred← citeshttps://doi.org/10.1097/bor.0b013e3282fb7caaopenalex-snapshot
Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis and seronegative arthritis
inferred← citeshttps://doi.org/10.1097/cpm.0b013e318250e566openalex-snapshot
Severe Lenalidomide-induced Interstitial Pneumonitis Requiring Mechanical Ventilation
inferred← citeshttps://doi.org/10.1097/md.0000000000004044openalex-snapshot
Diffuse alveolar damage in a patient with rheumatoid arthritis under prolonged leflunomide treatment
inferred← citeshttps://doi.org/10.1097/rhu.0000000000001336openalex-snapshot
Methotrexate-Induced Pneumonitis in Rheumatoid Arthritis: Long-term Treatment With Tofacitinib Therapy.
inferred← citeshttps://doi.org/10.1097/rhu.0b013e3181c3f87eopenalex-snapshot
Successful Treatment of Leflunomide-Induced Acute Pneumonitis With Cholestyramine Wash-Out Therapy
inferred← citeshttps://doi.org/10.1155/2013/759760openalex-snapshot
The Multifaceted Aspects of Interstitial Lung Disease in Rheumatoid Arthritis
inferred← citeshttps://doi.org/10.1177/1759720x15612250openalex-snapshot
Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review
inferred← citeshttps://doi.org/10.1183/09059180.00008014openalex-snapshot
Rheumatoid arthritis-associated lung disease
inferred← citeshttps://doi.org/10.1186/ar4075openalex-snapshot
Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate
inferred← citeshttps://doi.org/10.14412/1995-4484-2014-451-457openalex-snapshot
PULMONARY INVOLVEMENT IN RHEUMATOID ARTHRITIS
inferred← citeshttps://doi.org/10.14412/1996-7012-2014-4-48-53openalex-snapshot
Interstitial lung involvement in rheumatoid arthritis
inferred← citeshttps://doi.org/10.1517/14740338.2011.560835openalex-snapshot
Leflunomide-induced interstitial pneumonitis might be a representative of disease-modifying antirheumatic drug-induced lung injury
inferred← citeshttps://doi.org/10.2165/11316650-000000000-00000openalex-snapshot
Benefit-Risk Assessment of Leflunomide
inferred← citeshttps://doi.org/10.2174/1874306401206010063openalex-snapshot
Drug Induced Interstitial Lung Disease
inferred← citeshttps://doi.org/10.3109/03009742.2013.868511openalex-snapshot
Five cases of interstitial lung disease after leflunomide was combined with methotrexate therapy
inferred← citeshttps://doi.org/10.3389/fmed.2022.837133openalex-snapshot
Interstitial Lung Disease in Rheumatoid Arthritis: A Practical Review
inferred← citeshttps://doi.org/10.3390/biomedicines11061755openalex-snapshot
Better Safe than Sorry: Rheumatoid Arthritis, Interstitial Lung Disease, and Medication—A Narrative Review
inferred← citeshttps://doi.org/10.3390/jcm9041082openalex-snapshot
Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows
inferred← citeshttps://doi.org/10.3724/sp.j.1264.2011.00021openalex-snapshot
Leflunomide and rheumatoid interstitial lung disease
inferred← citeshttps://doi.org/10.3899/jrheum.110704openalex-snapshot
Mortality and Incidence of Malignancy in Korean Patients with Rheumatoid Arthritis
inferred← citeshttps://doi.org/10.4078/jkra.2009.16.2.71openalex-snapshot
The Efficacy and Safety of Leflunomide in the Treatment of Rheumatoid Arthritis
inferred← citeshttps://doi.org/10.5603/piap.2015.0007openalex-snapshot
Leflunomide-Induced Acute Interstitial Pneumonia in a Patient Treated for Rheumatoid Arthritis
inferred← citeshttps://doi.org/10.5799/jcei.328697openalex-snapshot
Pulmonary Nodulosis Associated with Leflunomide Therapy in Rheumatoid Arthritis: Report of Four Cases and Review of the Literature
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.